the aid library

LIST OPTIONS

Filter

2827

Sort by:

Direction:

Download (38)

View PDF (28)

Ready to Use Therapeutic Food (RUFT) and the WHO Essential Medicines List

CMAM Forum (2018) CC

Severe Acute Malnutrition (SAM) is one of the greatest child survival challenges in the world today and reportedly affects more than 16.2 million children each year1. High impact, proven treatment interventions exist yet sadly approximately only 3.2 million children with SAM have access to treatme... more

Download (122)

View PDF (169)

Responsible use of antibiotics in aquaculture

Hernández Serrano, P. Food and Agriculture Organization (FAO) (2005) C2

In aquaculture, antibiotics have been used mainly for therapeutic purposes and as prophylactic agents. The contribution to antimicrobial resistance of antibiotics used in aquaculture is reviewed here, using a risk analysis framework. Some recommendations on responsible conduct in this context are pr... more

Download (221)

View PDF (261)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (148)

View PDF (224)

Therapeutics and COVID-19: living guideline (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

3 March 2022 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ... more

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (124)

View PDF (177)

Therapeutics for Ebola virus disease
recommended

World Health Organization WHO (2022) C_WHO

The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il... more

Download (1866)

View PDF (1339)

Selection and Use of Essential Medicines 2021
recommended

World Health Organization WHO (2021) C_WHO

The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo... more

Download (288)

View PDF (451)

Executive summary: the selection and use of essential medicines 2021

World Health Organization WHO (2021) C_WHO

Report of the 23rd WHO Expert Committee on the selection and use of essential medicines This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)... more

Download (123)

View PDF (160)

Statement on the Use of Ivermectin for COVID-19

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1

Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States. Currently... more

Download (89)

View PDF (96)

Acute schistosomiasis, a diagnostic and therapeutic challenge

Jauréguiberry S., Paris L., Caumes E. (2010) C2

Clin Microbiol Infect 2010; 16: 225–231 Abstract In non-endemic countries, acute (invasive) schistosomiasis (AS) is typically seen in non-immune travellers, whereas chronic schistosomiasis is more frequently diagnosed in immigrants. Travellers with AS initially present with non-specific signs such... more

Download (103)

View PDF (613)

Curbing Antimicrobial Resistance in Food Animal Production

Johns Hopkins Center for a Livable Future (2016) C2

Antimicrobials are widely used in food animal production, and use is rapidly increasing. In an era of growing demand for animal products, there is an increasing trend towards the industrial production of food animals, especially in lower- and middle-income countries (LMICs). One hallmark of this me... more

Download (290)

View PDF (280)

Standard Treatment Guidelines and Essential Medicines List for South Africa : Primary Healthcare Level 2020 edition

the Essential Drugs Programme, the PHCAdult Hospital Level Expert review Committee, the National Essential Medicines List Committee National Department of Health South Africa (2020) CC

The PHC STGs and EML should be used by healthcare workers providing care at clinics, community health centres, and gateway clinics at hospitals. Pharmaceutical and Therapeutics Committees (PTCs) are responsible for ensuring the availability of medicines listed in the PHC EML at those facilities, as... more

Download (242)

View PDF (178)

WHO standard acupuncture point locations in the Western Pacific region

World Health Organization (WHO) (2009) C_WHO

Acupuncture has been practised for more than 2500 years in the Western Pacific Region and has become a global therapeutic method in recent decades. However, it was reportedthat acupuncturists differed by up to 25% in the acupuncture points they used, raising doubts and uncertainty regarding the effi... more

Download (155)

View PDF (183)

Drugs to prevent COVID-19: living guideline

World Health Organisation (WHO) (2023) C_WHO

The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to prevent COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform. Guidelines ... more

Download (38233)

View PDF (2324)

Emergency Drug Guidelines. Fiji

Ministry of Health, Fiji World Health Organization WHO (2008) C_WHO

The publication of the Second Edition of the Emergency Drug Guidelines represents the culmination of the efforts of the National Drugs and Therapeutics Committee (NDTC) to publish clinical drug guidelines for common diseases seen in Fiji. These guidelines are targeted for health care professionals w... more

Download (254)

View PDF (164)

Community- Based Management of Acute Malnutrition (CMAM)

World Vision International (2017) C1

Community-Based Management of Acute Malnutrition (CMAM) is a decentralised community-based approach to treating acute malnutrition. Treatment is matched to the nutritional and clinical needs of the child, with the majority children receiving treatment at home using ready-to-use foods. In-patient car... more

Download (31)

View PDF (27)

Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps

Blanco, I.; Diego, I.; Bueno, P. et al. (2019) CC2

Existing data on chronic obstructive pulmonary disease (COPD) prevalence are irregularly distributed around the world, and in many geographic regions data are scarce or even nonexistent. This fact hinders the implementation of adequate preventive and therapeutic interventions to reduce the high burd... more

Download (85)

View PDF (597)

Current Treatments to Control African Trypanosomiasis and One Health Perspective

Venturelli, A.; Tagliazucchi, L.; Lima, C.; Venuti, F. et al. MDPI Microorganisms (2022) CC

Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reserv... more

Download (89)

View PDF (721)

The Role of Empathy in Health and Social Care Professionals - Review

Moudatsou, M.; A. Stavropoulou, A. Philalidis, et al. Healthcare Journal (2020) CC

Healthcare 2020, 8(1), 26; https://doi.org/10.3390/healthcare8010026 The current article is an integrative and analytical literature review on the concept and meaning of empathy in health and social care professionals. Empathy, i.e., the ability to understand the perso... more

Download (162)

View PDF (179)

Revised COVID-19 Testing Strategy
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

Second edition. June 2022. This revised guidance recommends that access to COVID-19 testing is decentralized as far as possible and made available at health facilities, and through the use of self tests to enable access to care and the mitigation of transmission. Testing should be prioritized for hi... more

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Therapeutics and COVID-19: living guideline (Arabic) recommended

Therapeutics for Ebola virus disease recommended

Selection and Use of Essential Medicines 2021 recommended

Revised COVID-19 Testing Strategy recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Therapeutics and COVID-19: living guideline (Arabic)
recommended

Therapeutics for Ebola virus disease
recommended

Selection and Use of Essential Medicines 2021
recommended

Revised COVID-19 Testing Strategy
recommended